X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
Listed Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
Details:
The acquisition accelerates Cosette’s women’s health portfolio, with a differentiated, commercial stage, patent protected product, Intrarosa (prasterone), the only prescription drug providing both estrogen and androgen for the treatment of moderate-to-severe dyspareunia.
Lead Product(s): Prasterone
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Intrarosa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cosette Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition June 08, 2023
Details:
Intrarosa is now available in this market as the first and only locally acting DHEA (dehydroepiandrosterone) treatment indicated for postmenopausal women experiencing moderate to severe symptoms associated with vulvovaginal atrophy (VVA).
Lead Product(s): Prasterone
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Intrarosa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Endoceutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 14, 2022
Details:
Transaction allows AMAG to advance its strategic focus on Feraheme, Makena and its pipeline, consistent with previously announced plans.
Lead Product(s): Prasterone
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Millicent Pharma Limited
Deal Size: $125.0 million Upfront Cash: $20.0 million
Deal Type: Divestment May 21, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
